leukemia
BeiGene, CLL Society Partner to Promote Biomarker Testing in CLL, SLL
The partnership will support a campaign intended to increase the use of genomic testing to guide personalized therapy and improve outcomes.
Aptose Partners With NCI to Study Tuspetinib in MyeloMATCH Trials
NCI will include the multi-kinase inhibitor in the umbrella trial evaluating targeted therapy combinations in AML and MDS patients.
Senti Biosciences Announces $37.6M PIPE Financing, Reports Early Data From Phase I CAR-NK Trial
The firm plans to put the proceeds toward further developing its cell therapy in CD33- or FLT3-expressing AML and for other R&D activities.
Pentixapharm Begins Phase I/II Trial of Radiopharmaceutical Agent in Leukemia
The trial will include patients with CXCR4-positive acute myeloid leukemia and acute lymphoblastic leukemia.
Syndax's Revuforj Garners FDA Approval for Refractory KMT2A-Altered Acute Leukemia
In the AUGMENT-101 trial, 21 percent of patients achieved complete remission plus complete remission with partial hematological recovery on the drug.
Jul 18, 2024